The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 40-47

  Bueno de Mesquita, J M ^a   Nuyten, D S A ^a   Wesseling, J ^a   van Tinteren, H ^a   Linn, S C ^a   van de Vijver, M J ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant systemic treatment; Breast cancer; Inter observer agreement; Inter observer variation; Pathological examination; Prognostic index

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OBSERVER VARIATION; ONLINE SYSTEM; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT INDICATION; TUMOR VOLUME;

EID: 70349088835     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp273     Document Type: Article

References (35)

1. Harris J. Staging of breast cancer. In Harris JR, Lippman ME, Morrow M, Osborne CK (eds): Disease of the Breast, 3rd edition. Philadelphia, PA: Lippincott Williams & Wilkins 2004; 653-667.
2. Kwaliteitsinstituut voor de Gezondheidszorg CBO, Vereniging voor Integrale Kankercentra, Nationaal Borstkanker Overleg Nederland. Adjuvante Systemische Therapie voor het Operabel Mammacarcinoom. Richtlijn Behandeling van het Mammacarcinoom 2004: 46-70.
3. Kwaliteitsinstituut voor de Gezondheidszorg CBO, Vereniging voor Integrale Kankercentra, Nationaal Borstkanker Overleg Nederland. Adjuvante Systemische Therapie voor het Operabel Mammacarcinoom. Richtlijn Behandeling van het Mammacarcinoom 2005 2005: 46-70.
4. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16(10): 1569-1583.
5. Todd JH, Dowle C, Williams MR et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987; 56(4): 489-492.
6. D'Eredita' G, Giardina C, Martellotta M et al. Prognostic factors in breast cancer: the predictive value of the Nottingham Prognostic Index in patients with a longterm follow-up that were treated in a single institution. Eur J Cancer 2001; 37(5): 591-596.
7. Kattan MW, Giri D, Panageas KS et al. A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy. Cancer 2004; 101(11): 2509-2515.
8. Blamey RW, Ellis IO, Pinder SE et al. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer 2007; 43(10): 1548-1555.
9. Olivotto IA, Bajdik CD, Ravdin PM et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005; 23(12): 2716-2725.
10. Ravdin PM, Siminoff LA, Davis GJ et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19(4): 980-991.
11. Hopton DS, Thorogood J, Clayden AD, MacKinnon D. Observer variation in histological grading of breast cancer. Eur J Surg Oncol 1989; 15(1): 21-23.
12. Theissig F, Kunze KD, Haroske G, Meyer W. Histological grading of breast cancer. Interobserver, reproducibility and prognostic significance. Pathol Res Pract 1990; 186(6): 732-736.
13. Robbins P, Pinder S, de KN et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995; 26(8): 873-879.
14. Frierson HF Jr, Wolber RA, Berean KW et al. Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 1995; 103(2): 195-198.
15. Sloane JP, Amendoeira I, Apostolikas N et al. Consistency achieved by 23 European pathologists from 12 countries in diagnosing breast disease and reporting prognostic features of carcinomas. European Commission Working Group on Breast Screening Pathology. Virchows Arch 1999; 434(1): 3-10.
16. Boiesen P, Bendahl PO, Anagnostaki L et al. Histologic grading in breast cancer-reproducibility between seven pathologic departments. South Sweden Breast Cancer Group. Acta Oncol 2000; 39(1): 41-45.
17. Dalton LW, Pinder SE, Elston CE et al. Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. Mod Pathol 2000; 13(7): 730-735.
18. Elston CW, Sloane JP, Amendoeira I et al. Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer 2000; 36(14): 1769-1772.
19. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351(27): 2817-2826.
20. Longacre TA, Ennis M, Quenneville LA et al. Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study. Mod Pathol 2006; 19(2): 195-207.
21. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98(4): 262-272.
22. Viale G, Regan M, Maiorano E et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25(25): 3846-3852.
23. Collins LC, Marotti JD, Baer HJ, Tamimi RM. Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. J Natl Cancer Inst 2008; 100(3): 218-221.
24. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002; 94(11): 852-854.
25. Roche PC, Suman VJ, Jenkins RB et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94(11): 855-857.
26. Perez EA, Suman VJ, Davidson NE et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006; 24(19): 3032-3038.
27. Schnitt SJ. Estrogen receptor testing of breast cancer in current clinical practice: what's the question? J Clin Oncol 2006; 24(12): 1797-1799.
28. Bueno-de-Mesquita JM, Linn SC, Keijzer R et al. Validation of 70-gene prognosis signature in node-negative breast cancer. Breast Cancer Res Treat 2008; Sep 26.
29. Bueno-de-Mesquita JM, van Harten W, Retel V et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007; 8(12): 1079-1087.
30. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 1991; 19(5): 403-410.
31. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25(1): 118-145.
32. van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319(19): 1239-1245.
33. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
34. Eifel P. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93(13): 979-989.
35. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998; 90(21): 1601-1608.